Sweden Moves to Boost Competitiveness in Clinical Trials with New National Partnership
A new report outlines strategies for Sweden to enhance its competitiveness in clinical trials through a national partnership.
Key Points
- • Sweden's new report focuses on strengthening its clinical trial competitiveness.
- • The establishment of a national partnership, Swetrial, is a key recommendation.
- • Key stakeholders include Region Stockholm, Region Skåne, and Lif.
- • The initiative is funded by Swelife and supported by Vinnova.
On June 18, 2025, a new report entitled "Stärkt svensk konkurrenskraft för kliniska prövningar" was released, outlining a strategic plan to enhance Sweden's competitiveness in clinical trials. The report identifies essential conditions, barriers, and opportunities for Sweden to fortify its standing as a research nation conducive to drug development investments. Key stakeholders involved in this initiative include Region Stockholm, Region Skåne, Västra Götalandsregionen, Lif, and SwedenBIO, demonstrating a collaborative effort across various sectors.
At the core of the report’s recommendations is the establishment of a national partnership known as Swetrial, which will be administered by Läkemedelsverket. This partnership is aimed at significantly improving Sweden's ability to attract investment in clinical trials, which is critical for advancing pharmaceutical research and development in the country. The initiative is financed through the strategic innovation program Swelife, with additional support from Vinnova.
The report includes specific guidelines for the implementation of Swetrial, emphasizing the importance of effective collaboration among different regions and stakeholders within the Swedish health and pharmaceutical industries. By following these recommendations, Sweden hopes to solidify its competitiveness and further enhance its reputation in the global clinical trials landscape.